Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis

Supportive Care in Cancer

Volumn 15, Issue 2, 2007, Pages 197-202

  Walter, Christian ^a   Grötz, Knut A ^a   Kunkel, Martin ^a   Al Nawas, Bilal ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Bisphosphonates; Mandible; Maxilla; Osteomyelitis; Osteonecrosis; Osteoradionecrosis; Prevalence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; JAW DISEASE; MALE; OSTEOMYELITIS; PLASMACYTOMA; PRIORITY JOURNAL; PROSTATE CANCER; RESIDENTIAL CARE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GERMANY; HUMANS; JAW DISEASES; MALE; MANDIBLE; MAXILLA; MIDDLE AGED; OSTEONECROSIS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 33847381429     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0120-z     Document Type: Article

References (35)

1. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961-2978
2. Fleisch H (2002) Development of bisphosphonates. Breast Cancer Res 4:30-34
3. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98:698-705
4. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57:3890-3894
5. Clezardin P, Fournier P, Boissier S, Peyruchaud O (2003) In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 10:173-180
6. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75-85
7. Perry CM, Figgitt DP (2004) Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64:1197-1211
8. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P (1992) Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 84:788-792
9. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663
10. Amin D, Cornell SA, Perrone MH, Bilder GE (1996) 1-Hydroxy-3- (methylpentylamino)-propylidene-1, 1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneimittelforschung 46:759-762
11. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115-1117
12. Carter GD, Goss AN (2003) Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48:268
13. Migliorati CA (2003) Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253-4254
14. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527-534
15. Grötz KA, Diel IJ (2005) Osteonekrose des Kiefers unter Bisphosphonat Langzeittherapie. Im Focus Onkologie 8:52-55
16. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538-6544
17. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V, Tonini G (2002) Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8:1080-1084
18. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061
19. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
20. Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, Zannettino AC (2004) The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 19:147-154
21. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317-7325
22. Hansen T, Kunkel M, Weber A, James Kirkpatrick C (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155-160
23. Dearden WF (1899) Fragilitas ossium amongst workers in Lucifer match factories. BMJ 2:270
24. Bernardi D, Barzan L, Franchin G, Cinelli R, Balestreri L, Tirelli U, Vaccher E (2005) Treatment of head and neck cancer in elderly patients: state of the art and guidelines. Crit Rev Oncol Hematol 53:71-80
25. Macdonald AG, Bissett JD (2001) Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy. Clin Oncol (R Coll Radiol) 13:135-137
26. Dawson LK, Nussey F, Oliver TB, Marks RC, Leonard RC (2001) Osteonecrosis of the femoral head following adjuvant chemotherapy for breast cancer. Breast 10:447-449
27. Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61:1238-1239
28. Kluth EV, Jain PR, Stuchell RN, Frich JC Jr (1988) A study of factors contributing to the development of osteoradionecrosis of the jaws. J Prosthet Dent 59:194-201
29. Curi MM, Dib LL (1997) Osteoradionecrosis of the jaws: a retrospective study of the background factors and treatment in 104 cases. J Oral Maxillofac Surg 55:540-544 (Discussion 545-546)
30. Reuther T, Schuster T, Mende U, Kubler A (2003) Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients-a report of a thirty year retrospective review. Int J Oral Maxillofac Surg 32:289-295
31. Robinson NA, Yeo JF (2004) Bisphosphonates-a word of caution. Ann Acad Med Singapore 33:48-49
32. Wagner W, Kuffner HD, Hartmann U (1986) Der bestrahlte Patient als Risikopatient bei zahnärztlich - chirurgischen Eingriffen. Dtsch Zahnarztl Z 41:440-443
33. Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29:321-327
34. Algur E, Macklis RM, Hafeli UO (2005) Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys 61:535-542
35. Schwartz HC (2004) Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg 62:763-764